Squarepoint
CLLS

Squarepoint’s Cellectis CLLS Stock Holding History

Squarepoint’s Portfolio CLLS Stock Details CLLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-16,455
Closed -$274K – 2171
2018
Q4 		$274K Buy
16,455
+3,626
+28% +$84.1K ﹤0.01% 1543
2018
Q3 		$362K Sell
12,829
-7,655
-37% -$220K ﹤0.01% 1452
2018
Q2 		$579K Buy
+20,484
New +$610K 0.01% 1119

Other funds holding CLLS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Squarepoint's CLLS Position: Q1 2019 in Review

Squarepoint sold out of Cellectis (CLLS) in Q1 2019, closing a stake of 16,455 shares — an estimated $274K sold.

Squarepoint first reported a position in CLLS in Q2 2018 and held it in 3 quarters. The position peaked at $579K in Q2 2018. 63 funds tracked by Wall St. Rank hold CLLS as of Q1 2019.

  • Squarepoint reported no remaining Cellectis position as of Q1 2019 after selling out during the quarter.
  • Squarepoint sold 16,455 Cellectis shares in Q1 2019, an estimated $274K.
  • Squarepoint first reported a position in Cellectis in Q2 2018 and held it in 3 quarters.
  • Squarepoint's Cellectis position peaked at $579K in Q2 2018.
  • 63 funds tracked by Wall St. Rank held Cellectis as of Q1 2019.

Based on Squarepoint's 13F filing for Q1 2019, filed 15 May 2019.